ReviewInternational journal of molecular sciences2023
Exploring the Role of Circulating Cell-Free RNA in the Development of Colorectal Cancer.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Roles and Applications of Circulating Tumor-Derived RNAs in Sarcoma Patients: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Present status of prostate cancer diagnosis, limitations, challenges, and future endeavors.Annals of medicine · 2026Review
- Liquid biopsy in Oncology: Results of a Delphi consensus study endorsed by the AIOM-SIAPEC/IAP-SIBioC-SIF Italian scientific societies.The journal of liquid biopsy · 2026Article
- Comprehensive Landscape of Diagnostic, Prognostic and Predictive Biomarkers in Colorectal Cancer: From Genomics to Multi-Omics Integration in Precision Medicine.Journal of personalized medicine · 2026Review
- Evaluation of Plasma-Derived Cell-Free RNA isolation methods using PCR-Based quantification.Molecular biology reports · 2026Article
- Review
- Cell-free RNAs in maternal peripheral blood as potential biomarkers of preeclampsia: a review.Reproductive biology and endocrinology : RB&E · 2025Review
- Validation of Prognostic Circulating Cell-Free RNA BiomarkersCurrent issues in molecular biology · 2025Article
- The impact of liquid biopsy in breast cancer: Redefining the landscape of non-invasive precision oncology.The journal of liquid biopsy · 2025Review
- Circulating Biomarkers of Thyroid Cancer: An Appraisal.Journal of clinical medicine · 2025Review
- Circulating lncRNA HOTAIR is a biomarker for pediatric acute lymphoblastic leukemia and mediator of miR-326 exosomal export.Scientific reports · 2025Article
- Nanozyme-based aptasensors for the detection of tumor biomarkers.Journal of biological engineering · 2025Review
- Lung Cancer Diagnosis and Prognostic Monitoring Through Cell-Free RNA via Liquid Biopsy.Therapeutics and clinical risk management · 2025Review
- Extracellular vesicles-derived extracellular RNA in bladder cancer: current progress and future prospects.Therapeutic advances in medical oncology · 2025Review
- Melanoma's New Frontier: Exploring the Latest Advances in Blood-Based Biomarkers for Melanoma.Cancers · 2024Review
- Liquid biopsy for evaluating mutations and chromosomal aberrations in cerebrospinal fluid from patients with primary or metastatic CNS tumors.The journal of liquid biopsy · 2024Article
- Liquid Biopsy in the Clinical Management of Cancers.International journal of molecular sciences · 2024Review
- Revisiting the standards of cancer detection and therapy alongside their comparison to modern methods.World journal of methodology · 2024Review
- A Comprehensive Review on Circulating cfRNA in Plasma: Implications for Disease Diagnosis and Beyond.Diagnostics (Basel, Switzerland) · 2024Review
- PFDN6 contributes to colorectal cancer progression via transcriptional regulation.eGastroenterology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Circulating tumor RNA (ctRNA) has recently emerged as a novel and attractive liquid biomarker. CtRNA is capable of providing important information about the expression of a variety of target genes noninvasively, without the need for biopsies, through the use of circulating RNA sequencing. The overexpression of cancer-specific transcripts increases the tumor-derived RNA signal, which overcomes limitations due to low quantities of circulating tumor DNA (ctDNA). The purpose of this work is to present an up-to-date review of current knowledge regarding ctRNAs and their status as biomarkers to address the diagnosis, prognosis, prediction, and drug resistance of colorectal cancer. The final section of the article discusses the practical aspects involved in analyzing plasma ctRNA, including storage and isolation, detection technologies, and their limitations in clinical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.